A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients

Not Applicable

• Conditions: FTLD-ALS spectrum

• Registration Number: JPRN-UMIN000038620
• Lead Sponsor: ational Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-12-01
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1)FTLD-ALS spectrum patients 1.Subjects with organic brain complications/disorders 2.Subjects with substance-related disorders 3.Subjects with severe physical complications/disorders or a history of such conditions 4.Subjects with claustrophobia 5.Pregnant, possibly pregnant or lactating women 6.From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study (at National Institutes for Quantum and Radiological Science and Technology) 7.Subjects with metallic medical device in the body (at Nagoya university) 8.Subjects with tattoo (at Nagoya university) 9.Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study 2)Healthy volunteers 1.Subjects with organic brain complications/disorders 2.Subjects with substance-related disorders 3.Subjects with severe physical complications/disorders or a history of such conditions 4.Subjects with metallic medical device in the body 5.Subjects with tattoo 6.Subjects with claustrophobia 7.Pregnant, possibly pregnant or lactating women 8.From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study (at National Institutes for Quantum and Radiological Science and Technology) 9.Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The associations between neurotransmitter systems evaluated by PET with (E)-[11C]ABP688 and MRI/MRS, and clinical symptoms.

Secondary Outcome Measures

Name	Time	Method
The associations between neurotransmitter systems evaluated by PET with (E)-[11C]ABP688 and MRI/MRS, and abnormally aggregated protein measured by PET with [18F]PM-PBB3 and [11C]PiB.